Lilly Asia Ventures Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 6
- Investments
- 217
- Portfolio
- 104
- Exits
- 42
Lilly Asia Ventures General Information
Description
Lilly Asia Ventures is a venture capital firm. The firm makes venture capital investments in the life sciences and healthcare sectors in Asia, with a focus on China. It was founded in 2008 and is based in Shanghai, China.
Contact Information
Website
www.lillyasiaventures.com
Year Founded
2008
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- Room 2909-14, No.168 Hubin Road
- Huangpu District
- Shanghai, 200021
- China
+86 00000000000
Lilly Asia Ventures Investments (217)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| GluBio Pharmaceutical | 28-Feb-2022 | Early Stage VC | 0000 | Drug Discovery | Startup | |
| 00000000 000000000 | 14-Feb-2022 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - General | |
| 0000 0000000000000 | 08-Feb-2022 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | |
| 000000000 | 09-Jan-2022 | 00000 00000 | 000.00 | Drug Discovery | Startup | |
| 0000000000 | 31-Dec-2021 | 00000 00000 | 00000 | Pharmaceuticals | Clinical Trials - Phase 1 | |
| 000000 0000000 000 | 13-Dec-2021 | 000 | 00000 | Clinics/Outpatient Services | Profitable | |
| 0000000 | 01-Dec-2021 | 00000 00000 | 0000 | Diagnostic Equipment | Product Development | |
| 0000000 | 15-Nov-2021 | 00000 00000 | 000.00 | Therapeutic Devices | Generating Revenue | 000 0000 00.0 |
| Singleron Biotechnologies | 09-Nov-2021 | Early Stage VC | 00000 | Diagnostic Equipment | Generating Revenue | |
| Correctseq | 08-Nov-2021 | Early Stage VC | 000.00 | Biotechnology | Startup |
Lilly Asia Ventures Exits (42)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| CinCor Pharma | 07-Jan-2022 | IPO | 00000 |
| 000000 00000000000 | 08-Jul-2021 | 000 | 00000 |
| 0000000 0000000000 | 28-Jun-2021 | 0000000 000000 | |
| 0000 000000000000 | 01-Jun-2021 | 000000000000000000 | 0000 |
| 0000 | 06-May-2021 | 000 | 000.00 |
| 0000000 0000000000 | 19-Mar-2021 | 000 | 00000 |
| 00000 000000000000 | 05-Feb-2021 | 000 | 00000 |
| 00000 0000000000 | 27-Jan-2021 | 000 | 00000 |
| Passage Bio | 22-Jan-2021 | Public Investment 2nd Offering | 00000 |
| Gracell | 08-Jan-2021 | IPO | 00000 |
Lilly Asia Ventures Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is available in the PitchBook Platform. To explore Lilly Asia Ventures‘s full profile, request access.
Request a free trialLilly Asia Ventures Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialLilly Asia Ventures Team (10)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Yi Shi Ph.D | Founder & Managing Partner | 00 | 0 | 0 | Shanghai, China |
| Fei Chen Ph.D | Managing Partner | 00 | 0 | Shanghai, China | |
| Jimmy Zhang | Partner | 0 | Shanghai, China | ||
| Judith Li | Partner | 00 | 0 | 0 | Shanghai, China |
| Stephen Lin | Partner | 0 | 0 | Shanghai, China |
Lilly Asia Ventures Co-Investors (360)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 23 | 0 | 00 |
|
|
| Hillhouse Capital Group | 00 | 0 |
|
|
|
| Qiming Venture Partners | 00 | 0 | 0 |
|
|
| Sequoia Capital China | 00 | 0 | 0 |
|
|
| Vivo Capital | 00 | 0 |
|
|